Seneca Biopharma is an other business based in the US. Seneca Biopharma shares (CUR) are listed on the NASDAQ and all prices are listed in US Dollars. Seneca Biopharma employs 5 staff and has a market cap (total outstanding shares value) of 0.00.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – CUR.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Seneca Biopharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Seneca Biopharma stock price (NASDAQ: CUR)
Use our graph to track the performance of CUR stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Seneca Biopharma financials
Gross profit TTM
$0
Return on assets TTM
0%
Return on equity TTM
0%
Profit margin
0%
Book value
$2.50
Market Capitalization
$4 million
TTM: trailing 12 months
Seneca Biopharma share dividends
We're not expecting Seneca Biopharma to pay a dividend over the next 12 months.
Seneca Biopharma overview
Seneca Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. The company was formerly known as Neuralstem, Inc.
Frequently asked questions
How many people work for Seneca Biopharma? Latest data suggests 5 work at Seneca Biopharma.When does the fiscal year end for Seneca Biopharma? Seneca Biopharma's fiscal year ends in December.Where is Seneca Biopharma based? Seneca Biopharma's address is: 20271 Goldenrod Lane, Suite 2024
20876,Germantown,USA
What is Seneca Biopharma's ISIN number? Seneca Biopharma's international securities identification number is: US81689B1035What is Seneca Biopharma's CUSIP number? Seneca Biopharma's Committee on Uniform Securities Identification Procedures number is: 64127R302
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
